Vera Therapeutics financials
$32.38−0.38%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 | FY21 Dec 31 |
|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | — |
| Gross profit | $0.00 | $0.00 | $0.00 | $0.00 | — |
| Gross margin | — | — | — | — | — |
| Operating income | -$315.5M | -$167.2M | -$102.0M | -$90.9M | -$34.4M |
| Net income | -$299.6M | -$152.1M | -$96.0M | -$89.1M | -$32.6M |
| Net margin | — | — | — | — | — |
| Diluted EPS | $-4.66 | $-2.75 | $-2.25 | $-3.35 | $-2.43 |
| EBITDA | -$315.0M | -$167.1M | -$102.0M | -$89.5M | -$34.2M |
| Operating cash flow | -$241.1M | -$134.7M | -$92.2M | -$67.6M | -$23.7M |
| Free cash flow | -$241.7M | -$135.7M | -$92.2M | -$67.7M | -$28.7M |
| Diluted shares | 64.2M | 55.3M | 42.7M | 26.6M | 13.4M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|
| Cash & equivalents | $354.7M | $92.6M | $45.7M | $43.5M | $79.7M |
| Short-term investments | $359.9M | $548.2M | $115.0M | $71.2M | $0.00 |
| Total debt | $74.8M | $50.7M | $49.9M | $24.8M | $4.9M |
| Total assets | $734.7M | $655.7M | $175.5M | $131.4M | $83.7M |
| Total liabilities | $130.2M | $78.5M | $73.9M | $54.5M | $14.2M |
| Shareholders' equity | $604.5M | $577.2M | $101.7M | $76.9M | $69.6M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology